Proinflammatory cytokines but not acute phase serum amyloid A or C-reactive protein, downregulate paraoxonase 1 (PON1) expression by HepG2 cells.
The expression of paraoxonase1 (PON1) during inflammation has been investigated in vitro. The alteration of steady state PON1 mRNA in HepG2 cells by interleukin-1beta (IL-1beta) and tumor necrosis factor-alpha (TNF-alpha), was investigated relative to acute-phase serum amyloid A (A-SAA) mRNA. PON1 mRNA expression by HepG2 cells was decreased within three hours of stimulation by IL-1beta or TNF-alpha. Relative to PON1 mRNA expression, the pattern of steady state A-SAA mRNA expression was altered reciprocally and inversely by IL-1beta. These findings suggested that the decrease in serum PON activity after abdominal surgery in our previous clinical study may be ascribed to a decrease in steady state PON1 mRNA expression by liver with proinflammatory cytokines.
Kumon
Yoshitaka
Y
Second Department of Internal Medicine, Kochi Medical School, Nankoku, Japan. kumony@kochi-ms.ac.jp
Nakauchi
Yuh
Y
Suehiro
Tadashi
T
Shiinoki
Tomoko
T
Tanimoto
Noriyasu
N
Inoue
Mari
M
Nakamura
Toshihiro
T
Hashimoto
Kozo
K
Sipe
Jean D
JD
D001053:Apolipoproteins / Q000494:pharmacology; D043303:Aryldialkylphosphatase; D002097:C-Reactive Protein / Q000378:metabolism*; D006528:Carcinoma, Hepatocellular / Q000276:immunology / Q000378:metabolism; D002352:Carrier Proteins; D002373:Cyclic AMP Receptor Protein / Q000494:pharmacology; D016207:Cytokines / Q000276:immunology* / Q000494:pharmacology; D015536:Down-Regulation; D004950:Esterases / Q000096:biosynthesis / Q000187:drug effects / Q000235:genetics*; D006801:Humans; D000685:Serum Amyloid A Protein / Q000378:metabolism* / Q000494:pharmacology
D001053:Apolipoproteins; D002352:Carrier Proteins; D002373:Cyclic AMP Receptor Protein; D016207:Cytokines; D000685:Serum Amyloid A Protein; D002097:C-Reactive Protein; D004950:Esterases; D043303:Aryldialkylphosphatase; C468406:PON1 protein, human